Caroline Seymour

Beth McLellan, MD, discusses radiation dermatitis prevention, scalp cooling equity, and the future of personalized oncodermatology in melanoma management.

Durvalumab plus BCG induction and maintenance yielded an HR of 0.68 vs BCG alone for DFS in BCG-naive, high-risk non–muscle-invasive bladder cancer.

Durvalumab added to BCG induction-maintenance achieved superior DFS versus BCG alone (HR 0.68; P=.0154) with fewer events and unreached median DFS in both arms. Early high-risk NMIBC events within 12 months were reduced and delayed (median 14.1 vs 8.3 months), while adequate BCG completion remained high (87% vs 93%).

An ITT reanalysis assigning 0-month suspension to non-suspenders addressed imbalance in suspension rates (90% combination, 86% monotherapy, 67% leuprolide), enabling less biased comparisons across arms.

Key Takeaways Priority review was granted for first-line sevabertinib in HER2 TKD–mutant advanced NSCLC, supported by cohort F ORR 71%, DOR 11.0 months, and DCR 89%. SOHO-01 is an open-label, single-arm, multicenter multicohort study using local blood/tissue testing for HER2 mutations, with BICR-assessed ORR and DOR per RECIST 1.1. Enrolled patients were largely female never-smokers with adenocarcinoma; 88% had baseline brain metastases, and Y772_A775dupYVMA predominated, highlighting a high-risk, CNS-involved cohort. Treatment-related toxicity was mainly grade 1–2 diarrhea, rash, paronychia, stomatitis, and anemia; accelerated approval in pretreated disease showed ORR 71% without prior HER2 therapy versus 38% post-ADC. SHOW MORE

Key Takeaways FDA authorized Dato-DXd for unresectable/metastatic TNBC in adults who are not PD-1/PD-L1 inhibitor candidates, establishing a first-line TROP2-directed ADC option in this subset. TROPION-Breast02 demonstrated OS improvement over chemotherapy (HR 0.79; median 23.7 vs 18.7 months; P=.0290), meeting statistical significance with clinically meaningful separation. Blinded independent central review showed substantial PFS gain (HR 0.57; median 10.8 vs 5.6 months; P<.0001), consistent with reduced progression or death risk. Objective response rate favored Dato-DXd (64% vs 30%), reinforcing higher antitumor activity than standard single-agent chemotherapy in metastatic TNBC. No new safety signals were reported, and ADC-associated toxicity profiles may be preferable to conventional chemotherapy, enabling alternative sequencing after prior multi-agent chemo-immunotherapy. SHOW MORE

Frontline darovasertib plus crizotinib improved PFS vs investigator’s choice of therapy in patients with HLA-A*02:01–negative metastatic uveal melanoma.

Findings from the OptimUM-02 trial may support a new potential therapeutic standard for patients with HLA-A*02:01–negative metastatic uveal melanoma.

Giredestrant plus palbociclib improved PFS numerically just shy of 5 months in the persevERA trial, but was deemed negative due to lack of statistical significance.